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Abstract 
The genome is organised into large scale structures in the interphase nucleus. Pericentromeric 
heterochromatin represents one such compartment characterised by histones H3 and H4 tri-methylated 
at K9 and K20 respectively and with a correspondingly low level of histone acetylation. HP1 proteins 
are concentrated in pericentric heterochromatin and histone deacetylase inhibitors such as trichostatin 
A (TSA) promote hyperacetylation of heterochromatic nucleosomes and the dispersal of HP1 
proteins. We observed that in mouse cells, which contain prominent heterochromatin, DNA 
topoisomerase II (topoII) is also concentrated in heterochromatic regions. Similarly, a detergent-
resistant fraction of topoII is associated with heterochromatin in human cell lines. Treatment with 
TSA displaced topoII from the heterochromatin with similar kinetics to the displacement of HP1. 
Topoisomerase II is the cellular target for a number of clinically important cytotoxic anti-cancer 
agents known collectively as topoisomerase poisons, and it has been previously reported that histone 
deacetylase inhibitors can sensitise cells to these drugs. While topoII appears to be the major target 
for most topoisomerase poisons, histone deacetylase-mediated potentiation of these drugs is 
dependent on topoII. We find that while prior treatment with TSA did not increase the quantity of 
etoposide-mediated topoII-DNA covalent complexes, it did result in a shift in their distribution from 
a largely heterochromatin-associated to a pan-nuclear pattern. We suggest that this redistribution of 
topoII converts this isoform of topoII to a effective relevant target for topoisomerase poisons.  
Introduction 
Post-translational modifications of histone amino terminal tails are important for chromatin dynamics 
and organisation. Methylation and acetylation of specific lysine residues, together with 
phosphorylation, polyADP-ribosylation and ubiquitylation modulate processes such as transcription, 
cell cycle progression, DNA damage responses, apoptosis and differentiation.
1, 2
 Histone acetylation is 
associated with transcription. In contrast, constitutive heterochromatin, which is generally 
transcriptionally inert, contains low levels of histone acetylation and is characterised by trimethylated 
H3 lysine 9 and H4 lysine 20.
3-5
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Histone acetylation is governed by the opposing actions of histone acetyl transferases (HATs) and 
histone deacetylases (HDACs). Alterations in the structure or expression of HATs and HDACs are 
frequently reported in cancers and are linked to tumour development. Consequently, HDAC inhibitors 
(HDACIs) are undergoing trials as anticancer agents.
6-9
 HDACIs alone exert an antiproliferative effect 
and promote apoptosis in cancer cell-line models, but in addition HDACIs have been shown to 
sensitize cells to the cytotoxic effects of other anticancer drugs, particularly topoisomerase II poisons. 
10-16
 Topoisomerase poisons such as etoposide and epirubicin are of great clinical importance and are 
widely used in cancer therapy.
17, 18
  
Topoisomerase II is an essential enzyme that allows the passage of one DNA duplex through a 
second. During its reaction cycle the dimeric enzyme introduces an enzyme-bridged DNA double-
strand break (DSB) in one double helix through which a second duplex can be passed. At this stage 
each topoisomerase monomer is coupled to one free end of the first duplex through a 5’-
phosphotyrosyl linkage. Topoisomerase poisons stabilise the enzyme-linked DSB, which is otherwise 
transient and rapidly re-ligated 
19-21
. The resultant topoisomerase II-DNA covalent complexes account 
for the cytotoxic properties of the drugs and are presumed to be converted to “frank” DSBs by repair 
processes and/or result in a damage response following collisions with transcriptional or replication 
machinery. Mammals possess two topoisomerase II isoforms,  and , encoded by the TOP2A and 
TOP2B genes respectively 
22, 23
. Although the isoforms have very similar enzymatic characteristics in 
vitro and share 70% amino acid identity, topoisomerase II and – have different though possibly 
overlapping roles in mammalian cells. Topoisomerase II is essential for cell viability and is required 
for chromosome decatenation after S-phase
20
, while top2null mice develop to term but die 
perinatally with neural developmental defects
24
. Recently, specific roles in transcription regulation 
and sperm chromatin remodelling have been uncovered for topoisomerase II25-27 The topoisomerase 
II isoform is the major target for most clinically-relevant topoisomerase poisons including etoposide 
and epirubicin 
12, 28, 29
 although the - isoform appears to contribute more for some topoisomerase 
poisons including mitoxantrone, mAMSA and XK469.
28-30
  
4 
 
Several mechanisms could explain the sensitization of cells to topoisomerase poisons by HDAC 
inhibitors
13, 15, 31
 but notably, it was recently reported that this potentiation is mediated specifically 
through topoisomerase II.12 This was shown for etoposide and epirubicin as well as mitoxantrone. 
HDACIs cause chromatin decondensation, which may affect access of topoisomerase to DNA or 
access of topoisomerase poisons to the enzyme,
14, 32, 33
 resulting in elevated DNA damage and 
cytotoxicity. HDACI treatment leads to global changes in histone acetylation levels, including 
hyperacetylation of heterochromatin and redistribution of the non-histone heterochromatin protein 
HP1.
34-37
 It follows that this may affect the distribution of topoisomerase II in the interphase nucleus. 
Indeed, enzymatically active topoisomerase II is concentrated in heterochromatin in mid-late S-
phase in HeLa cells and is delocalised by the HDACI TSA.
38
 We have studied the nuclear distribution 
of topoisomerase II and show here that TSA leads to its redistribution in the nucleus and a change in 
the pattern of topoisomerase II-DNA complexes induced by etoposide in favour of a more 
euchromatic pattern. We suggest that altering the distribution of topoisomerase II in the nucleus and 
thus topoisomerase II-DNA adducts across the genome converts topoisomerase II into a more 
clinically useful target for topoisomerase poisons including etoposide.  
Materials and Methods 
Cell culture and reagents. Mouse C127I cells and A549 human lung carcinoma cells were acquired 
from European Collection of Cell Cultures (ECACC). Both cell lines were cultured in DMEM 
containing 10% FCS and antibiotics. Trichostatin A (Sigma) was dissolved in water and was added to 
cell cultures at between 2nM and 80 nM. VPA (Sigma) was added to cultures at the concentrations 
indicated in the text. Rabbit polyclonal antibodies 18511, 18513,
39
 3535 and 30400 were generated in 
house and their specificity was confirmed by Western blotting with whole cell extracts and purified 
recombinant topoisomerase II and . Anti topoisomerase II mab H-8 was from Santa Cruz, mouse 
MAB anti-fibrillarin 18380 and anti-HP1rat MAB MAC353 were from Abcam, mouse anti-H2AX 
MAB was from Millipore. 
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Growth inhibition assays.  Control (untreated) cells or cells incubated in medium containing VPA at 
1.6 or 8mM (10% and 50% of IC50 respectively) for 72 hours were trypsinised and plated into 96 well 
plates containing combinations of VPA (0, 1.6 or 8mM) and either vehicle or a dose range of 
topoisomerase II poison.  Plates were incubated for 72 hours under normal conditions, after which 
relative cell growth was determined by XTT assay (Roche) according to the manufacturer’s 
instructions. Optimum cell plating density was determined from growth curves. Data was normalized 
to the growth obtained with VPA alone. Assays were performed at least in triplicate and IC50 and PF50 
values were calculated. Potentiation factors (PF50) are the ratio of the concentration of topoisomerase 
poison required to achieve a 50% growth inhibition (IC50) in the absence of VPA to that in the 
presence of VPA. 
Immunofluorescence analysis. Cells were grown on glass cover slips. For standard paraformaldehyde 
fixation, coverslips were briefly washed in PBS, immersed in 4% paraformaldehyde in PBS for 10 
minutes at room temperature and then permeabilised by incubation in KCM+T [120 mM KCl, 20 mM 
NaCl, 10 mM TRIS-HCl, pH 7.5, 0.5 mM EDTA, 0.1% (v/v) Triton X-100] for 5 minutes. Coverslips 
were then blocked for 1 hour at room temperature with 10% dried milk powder, 5% BSA in KCM+T. 
First and second antibody incubations were in blocking buffer for 1 hour each at room temperature. 
Washes were carried out using KCM+T. Second antibodies were Alexa Fluor-488 or Alexa Fluor-594 
conjugated (Invitrogen). After second antibody incubation and washing, coverslips were mounted on 
slides with Vectashield containing DAPI and were sealed with nail varnish. For CSK extraction, 
coverslips were incubated on ice for 5 minutes in CSK buffer [10mM Pipes (pH 7.0), 100 mM NaCl, 
300 mM sucrose, 3 mM MgCl2, 1 mM EGTA 0.5% Triton-X100] containing protease inhibitors, 
before paraformaldehyde fixation and immunostaining. For DRT extraction, coverslips were extracted 
once on ice in [30 mM HEPES, 65 mM Pipes, 10 mM EGTA, 2 mM MgCl2, pH 6.9 with 350 mM 
NaCl, 0.5% Triton X-100] containing protease inhibitors for two minutes with occasional gentle 
agitation. Cells were then fixed for 10 minutes in 4% paraformaldehyde in PBS before 
immunostaining as above. Images were obtained using an Olympus IX81 motorized microscope fitted 
with a Hamamatsu Orca-AG monochrome camera. Z-stacks were collected using a 40X objective 
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(PlanS Apo, NA 0.95) at 0.2 µm intervals or using a 60X objective and OptiGrid confocal (Qioptiq) at 
0.3 m intervals. Iterative deconvolution was performed using Volocity software (Improvision). 
Western blotting. Cells were grown in 9cm tissue culture flasks. Whole cell extracts were prepared, 
separated by SDS PAGE and blotted onto nitrocellulose membranes as described previously.
40
 
Quantitative immunofluorescence.  Cells were grown on glass coverslips and immunostained as 
above. Topoisomerase II was detected using the primary antibodies indicated and Alexa Fluor 594-
conjugated second antibodies (Invitrogen). Microscopy was performed using an Olympus IX81 
motorized microscope with a 10X objective (UPlanFLN, NA 0.3) and employing a 120W X-Cite 
illumination system. Greyscale images were collected with a Hamamatsu Orca-AG camera with 2x2 
binning. Images were background and shade corrected as described previously.
41, 42
 Fluorescence 
intensity (integrated fluorescence) per nucleus was determined for DAPI and Alexa Fluor 488 
channels using Volocity Quantitation software (Improvision). Data was plotted using Graphpad 
Prism. 
Results 
A fraction of topoisomerase II is concentrated in heterochromatin 
Exposure of cultured cells to HDAC inhibitors results in cell cycle arrest and apoptosis. Prolonged 
exposure to low doses leads to chromatin decondensation associated with hyperacetylation of histones 
H3 and H4. In mouse cells under these conditions, pericentromeric heterochromatin relocates from a 
largely perinucleolar to a more peripheral distribution and in mouse and human cells, HP1 proteins 
become dissociated from heterochromatic regions.
34, 36
 In the light of this HDAC-mediated chromatin 
remodelling, and the role of topoisomerase II in sensitisation of cells to topoisomerase poisons by 
HDAC inhibitors, we hypothesised that HDAC inhibitors such as TSA or VPA may alter the 
subnuclear distribution of topoisomerase II. This, either directly or through increased accessibility of 
decondensed chromatin could lead to increased cytotoxicity associated with topoisomerase poisons. 
Previous studies have reported differing subnuclear distributions for topoisomerase II. 
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Topoisomerase II has variously been reported to be concentrated in the nucleoli or at the periphery 
of heterochromatic regions in fixed cells,
43-45
 and in live cells,
45
 while others have not found the 
protein to be specifically nucleolar.
39, 46
 The reasons for these differences are not clear, but probably 
reflect, at least in part, species differences and differences in specimen preparation. Nucleoli of mouse 
cells for example are associated at their periphery with AT-rich pericentromeric heterochromatin, 
which clusters in so-called chromocentres around centromeres. These chromocentres can be readily 
visualised in fluorescence microscopy of Hoechst or DAPI stained cells or with antibodies against 
HP1 proteins (Fig. 1A & Fig. S1). Heterochromatin in human cells by contrast, is less easily 
visualised. We show here that in mouse epithelial cells, under standard paraformaldehyde fixation 
conditions and using a series of characterised antibodies, that topoisomerase II has a nucleoplasmic 
distribution, with an increased concentration in chromocentres as identified by DAPI and anti-HP1 
staining (Fig. 1A). Although not excluded from nucleoli, topoisomerase II did not appear to be 
concentrated in these regions (see Figs 1A & 2). By contrast, topoisomerase II was distributed more 
evenly throughout interphase nuclei (see Fig 1B). Since chromocenters are largely clustered around 
nucleoli in mouse cells it was important to unequivocally distinguish between nucleolar and 
heterochromatic topoisomerase II staining. This was achieved by co-staining cells with anti-
topoisomerase IIβ and either anti-HP1 to identify heterochromatin or anti-fibrillarin to identify 
nucleoli. As shown in Fig. 2A, regions of intense topoisomerase II staining were largely non-
overlapping with the fibrillarin signal, but almost coincident with the HP1 and DAPI signals, which 
largely clustered around the outside of nucleoli. Consistently, centromers, as visualised by CENP-B 
staining, were contained within the regions of intense topoisomerase II (and HP1and DAPI) 
staining (Fig 2. B) 
TSA mobilises topoisomerase II from heterochromatin 
As alluded to above, prolonged exposure of mouse cells to the HDAC inhibitor TSA results in histone 
hyperacetylation and movement of heterochromatin clusters from a largely perinucleolar to a more 
peripheral distribution and dissociation of heterochromatin protein HP1. Since like HP1, 
topoisomerase II is concentrated in heterochromatin in C127I cells, we hypothesised that TSA 
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treatment would also lead to its redistribution. C127I cells were treated with TSA concentrations from 
2 to 80 nM for 2 or 5 days and then examined for topoisomerase II and HP1 distribution by 
immunofluorescence. After 5 day’s exposure to TSA, topoisomerase II and HP1 both showed a 
progressive dissociation from heterochromatic regions (as visualized by DAPI staining) with dose of 
TSA (Fig. 3). After 5 day’s exposure to 50 nM TSA, little or no heterochromatic concentration of 
either protein was apparent. After 2 days exposure to 50 nM TSA most topoisomerase II and HP1 
was displaced from heterochromatin. After 5 day’s exposure to 50 or 80 nM TSA, most cells appeared 
larger and flatter then untreated cells. Median topoisomerase II immunofluorescence per cell was 
increased almost two fold by TSA (Fig. 4A). This may reflect increased antigen accessibility, but 
notably median DNA content per nucleus was also increased, as assessed by quantitative DAPI 
fluorescence (Fig. 4C), consistent with accumulation of cells in G2 or with aberrant chromosome 
numbers resulting from TSA-induced mitotic defects and in addition, the nuclei of TSA treated cells 
are larger than those of untreated cells (see Fig. 3), Topoisomerase II protein levels were not 
changed by TSA in Western blot analysis where protein loading was standardised by micrograms of 
protein loaded (Fig. 4D). By comparison, it was previously noted that HDACIs did not significantly 
alter topoisomerase II protein level in human MCF7 cell extracts12. The level of HP1 
immunofluorescence remained unchanged by TSA (Fig. 4B), consistent with previous observations.
34 
When topoisomerase IIdissociated from heterochromatin it appeared in a fine speckled pattern 
throughout the nucleus and was occasionally excluded from heterochromatic regions (Fig. 6 fourth 
and fifth rows). 
Effect of HDAC inhibition on etoposide-induced topoisomerase-DNA complexes. 
The topoisomerase II reaction mechanism allows the passage of one DNA duplex through another by 
transiently cleaving the first DNA helix to create an enzyme-bridge DNA gate through which the 
second duplex is transported. The break is subsequently ligated and the DNA structure restored.
19-21
 
During the cleavage reaction, a covalent enzyme-DNA intermediate is formed between a tyrosine 
residue of each topoisomerase II monomer and the 5’-phosphate group of the cleaved DNA. This 
enzyme-bridged double-strand break normally exists transiently, but the action of topoisomerase 
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poisons such as etoposide is to stabilise these intermediates. Both topoisomerase II and  are targets 
for etoposide, and etoposide-induced topoisomerase II-DNA complexes can be visualised and 
quantified using a fluorescence microscopy based method (Trapped in AgaRose DNA 
ImmunoStaning, or TARDIS).
42
 This method involves ionic detergent and salt extraction of agarose-
embedded cells, resulting in removal of proteins not covalently coupled to the nuclear DNA, which is 
too bulky to elute from the agarose. Covalently coupled proteins are then detected by 
immunofluorescence. In a variation of this approach adherent cells are extracted in a similar fashion 
on glass coverslips under slightly less harsh conditions (DRT extraction) without agarose 
embedding.
38
 We used this latter technique to examine the effect of TSA treatment on both the 
quantity and subnuclear distribution of topoisomerase II-DNA complexes. While very low levels of 
nuclear topoisomerase II fluorescence were observed in DRT-extracted control cells, in cells treated 
with etoposide topoisomerase II immunofluorescence was easily detectable (Figs 5 & 6). The 
median immunofluorescent signal in DRT-extracted, etoposide-treated cells corresponded to 
approximately 20% of the total topoisomerase II complement measured in normally fixed (i.e. non-
extracted) cells (Fig. S2). From knowledge of the action of etoposide, and analogous experiments 
employing the more harsh extraction conditions of the TARDIS protocol,
42, 47, 48
 we conclude that the 
etoposide-induced topoisomerase II signal in DRT-extracted cells corresponds to covalent 
topoisomerase-DNA complexes. Notably, prior exposure to TSA (5 days 50nM) caused a small 
decrease in the median levels of etoposide-induced, extraction resistant topoisomerase II 
immunofluorescence when antibodies 18513 or 30400 were used, but did not significantly affect the 
signal with antibody 3535 (Fig. 5). 
In cells treated with etoposide for 2 hours before DRT extraction, topoisomerase II as detected by 
antibody 18513 had a clustered appearance, with bright areas coincident with the bright DAPI regions 
(Fig. 6A). This heterochromatic pattern was apparent in more than 70% of cells, while the remainder 
displayed a more diffuse, speckled pattern. The variation in pattern between cells may have been due 
to the short drug exposure in an asynchronous population of cells. In contrast, little if any 
heterochromatic concentration of extraction-resistant topoisomerase II was apparent in cells pre-
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treated with TSA before exposure to etoposide (Fig. 6A and compare Fig. 6 D&F). Results were 
similar with antibody 30400 and 3535. Thus, consistent with the TSA-induced redistribution of total 
topoisomerase II (see Fig. 2), the nuclear distribution of etoposide topoisomerase IIβ-DNA 
complexes is altered by TSA, to a more euchromatic pattern.  
Notably, TSA treatment alone did not significantly affect the quantity of DRT extraction-resistant 
topoisomerase II (Fig S2), nor did it affect the magnitude of etoposide induced histone H2AX 
phosphorylation, a marker for DNA double-strand breaks (not shown). However, we did find that it 
had an unexpected effect on the background pattern of H2AX. In control cells, H2AX is present in a 
faint speckled pattern in the nucleus, typically with one or a small number of bright foci, presumably 
originating from spontaneous DNA double-strand breaks (DSBs). However, in cells exposed to TSA 
for 5 days, H2AX was concentrated almost exclusively adjacent to large chromocentres (see Fig. 7). 
These TSA-induced H2AX foci were not as intense as those induced by etoposide, which also form 
predominantly outside heterochromatin,
49
 but contributed to an overall increase in background 
H2AX (Fig. 7A&B). Notably, it has recently been demonstrated that HDAC inhibition slows 
replication and leads to replication-associated DNA damage and H2AX phosphorylation,
50
 and we 
suspect that this is likely to be the cause of the TSA-induced peri-heterochromatic H2AXseen here. 
Thus increased background h2AX phosphorylation and the redistribution of topoisomerase IIare 
likely to be independent effects of the TSA-mediated remodelling of heterochromatin. 
The effect of HDACIs on the distribution of topoisomerase IIβ in human cells. 
Since HDACIs have been shown to potentiate topoisomerase poisons in human cancer cell lines, we 
also examined the effect of TSA and valproic acid (VPA) on topoisomerase II distribution in the 
human lung cancer cell line A549. Topoisomerase II was distributed in a nucleoplasmic pattern, with 
some concentration in the perinucleolar regions of most cells (Fig. 8A). The perinucleolar pattern was 
more pronounced when cells were permeabilised prior to fixation (Fig. 8B). Nucleoli of human cells 
are typically surrounded by clusters of heterochromatin identified by late replication timing, histone 
methylation and the presence of HP1 proteins.
4, 49
 In human cells, HP1 gives the most robust 
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pericentromeric staining pattern of the three HP1 species.
36, 51
 When we compared the distribution of 
HP1 to that of topoisomerase II, HP1 substantially coincided with the areas of brightest 
topoisomerase II signal (Fig. 8C). When cells were treated with TSA or VPA, topoisomerase II 
adopted a more pan-nuclear distribution, as was observed following HDACI treatment of mouse cells 
(Fig. 3). HP1 still presented a focal distribution under these conditions, as observed previously,36 but 
these foci were no longer associated with bright topoisomerase II staining (Fig. 8C). Thus, as in 
mouse C127I cells, topoisomerase II is partially concentrated in heterochromatic regions of the 
nucleus of A549 cells and is redistributed into a more uniform pattern upon HDACI treatment. We 
also investigated the distribution of topoisomerase II in two human lymphoblastoid cell lines K562 
and Nalm-6. Topoisomerase II appeared nucleoplasmic in distribution in these cells, but after mild 
detergent extraction (CSK buffer) the remaining topoisomerase II was concentrated in the DAPI-
bright heterochromatic regions surrounding nucleoli or at the nucleolar periphery (Fig S3), similar to 
the distribution in A549 cells. 
Topoisomerase IIβ  mediates the potentiating effect of HDACI 
We investigated the ability of the HDACI valproic acid to potentiate the growth inhibitory/cytotoxic 
effects of topoisomerase poisons in A549 cells using a series of topoisomerase poisons with different 
selectivities for topoisomerase II and –, see Table 1 & Table S1. The most robust potentiation was 
observed with mitoxantrone and mAMSA, while marginal potentiation was obtained for etoposide 
and no significant effect was seen for doxorubicin or epirubicin. Cells lacking topoisomerase II have 
previously been shown to be resistant to mitoxantrone and mAMSA,
28, 29
 indicating a significant role 
for this isozyme in the cytotoxicity of these drugs, whereas the degree of resistance to etoposide or 
doxorubicin in topoisomerase II null cells was smaller. Similarly, we found the IC50 for 
mitoxantrone in growth inhibition assays is five times higher in topoisomerase IInull Nalm-6 cells 
than in their wild type counterparts while the ratio is only 2.8 for etoposide (data not shown). Thus, 
these data support previous work
12
 identifying a functional interaction between topoisomerase II and 
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HDAC inhibitors such as VPA in the synergistic action of histone deacetylase inhibitors with 
topoisomerase poisons. 
 
What causes topoisomerase IIβ to be retained in heterochromatin? 
The very similar subnuclear localization of topoisomerase II and HP1 and their parallel dispersal 
from heterochromatin following TSA treatment suggests that the two proteins might interact in a 
protein-protein complex. Another piece of evidence that suggests this is the very similar phenotype of 
mice null for TOP2b and CBX1, the genes encoding topoisomerase II and HP1 respectively. Both 
TOP2b and CBX1 null mice develop apparently normally in utero, but die perinatally from respiratory 
failure due to failure to innervate the diaphragm.
24, 52
 We carried out a co-immunoprecipitation 
experiment to determine whether HP1 and topoisomerase II exist in a stable protein complex. 
While antibodies 18513 and MAC353 efficiently precipitated their cognate antigens (topoisomerase 
II and HP1 respectively), 18513 immunoprecipitates did not contain detectable HP1 and MAC353 
did not specifically precipitate topoisomerase II (data not shown). Thus, topoisomerase II and 
HP1 do not exist in a protein complex, at least not one that is stable under the conditions in which 
the cell extracts were prepared. So the heterochromatic accumulation of topoisomerase II can 
probably not be explained by association with HP1. Other candidates include interaction with 
another heterochromatin protein such as HP1 or KAP1 or with a modified histone such as H3K9me3 
(involved in targeting HP1)3 or H4K20me3. Whether any of these features are involved remains to 
be elucidated. Notably, topoisomerase II has previously been shown by photo bleaching studies to be 
quite mobile within the nucleus,
45
 thus interactions resulting in the observed heterochromatic 
concentration of topoisomerase II are presumable not of high affinity.  
Discussion 
Several mechanisms have been proposed to account for the sensitisation of cells to topoisomerase 
poisons by HDACIs. These include modulation of apoptotic pathways 
15
 and the general 
decondensation of chromatin following histone hyperacetylation, leading to increased DNA damage. 
13 
 
For example, SAHA and VPA cause chromatin decondensation in MCF7 cells as viewed by EM and 
DNase sensitivity.
11, 12
 This decondensation may allow greater access or accumulation of 
topoisomerase poisons in chromatin. Similarly, prolonged VPA treatment (48 hr) has been shown to 
result in reduction in HP1, DNMT1, SMC1 and SMC3 protein levels in MCF7 cells, though this was 
not observed in mouse cells for any of the HP1 isotypes.
34
 Our findings add to this chromatin-
mediated mechanism by demonstrating a redistribution of topoisomerase II within the nucleus 
following HDAC inhibition analogous to that previously observed for HP1. Specifically we find that 
in mouse C127I cells, which possess easily identifiable heterochromatic foci, topoisomerase II is 
concentrated in heterochromatin and redistributes to a speckled pan-nuclear pattern upon TSA- 
treatment (Figs 1-3 & S1). Previous photo-bleaching studies have shown that topoisomerase II is 
relatively mobile in the nucleus,
45
 thus association with heterochromatic or other structures is likely to 
be transient with exchange between compartments the equilibrium of which is altered by 
hyperacetylation of heterochromatin during HDACI treatment. 
Human cells do not contain the prominent chromocentres that are present in mouse cells, but 
topoisomerase II was concentrated in the perinucleolar region and in foci co-localising with HP1 in 
A549 human lung carcinoma cells. Notably though, topoisomerase IIwas not found in the barr-body 
in female human cells (E. Heard, personal communication), suggesting that its observed accumulation 
is limited to constitutive heterochromatin. As was observed in mouse cells, topoisomerase II was 
redistributed following TSA or VPA treatment (Fig. 8). TSA also altered the distribution of etoposide-
induced topoisomerase II-DNA complexes. In non-TSA treated C127I cells, adducts were 
concentrated in heterochromatic regions, reflecting the distribution of the enzyme in these cells, while 
after TSA treatment, adducts were distributed more evenly throughout the nucleus.  
We have not addressed the HDAC specificity of the observed topoisomerase II redistribution, but we 
note that HDAC2 was found to be the predominant target in MCF7 cells for HDACIs with regards to 
chromatin decondensation, downregulation of HP1 and other chromatin proteins and potentiation of 
epirubicin cytotoxicity.
33
 We have employed TSA and VPA in the work reported here. Both inhibit 
14 
 
HDAC2, although VPA but not TSA selectively induces proteasomal degradation of HDAC2.
53
 In 
addition, topoisomerase II and II physically interact with HDAC1 and HDAC2 and topoisomerase 
II is associated with HDAC1 in the NuRD complex.16, 54 Previous descriptions of the intranuclear 
distribution of topoisomerase II have varied in the literature.39, 43-46 This may reflect the dynamic 
nature of topoisomerase IITopoisomerase IIis recruited to the promoters of certain genes during 
transcriptional activation 
25, 26
 and it is possible that the HDACI-induced redistribution of 
topoisomerase II reported here reflects the normal dynamic behaviour of the protein during the 
execution of transcriptional programs, though this possibility remains to be explored. We have 
consistently observed topoisomerase II to be concentrated in chromocentres in untreated fixed 
mouse cells (Fig. 1-3 & S1). Notably, this distribution is mirrored in the pattern of topoisomerase II-
DNA adducts formed in living cells by etoposide (Fig. 6), arguing against the observed pattern being 
an artefact of fixation.  
The cytotoxic potential of topoisomerase poisons such as etoposide is mediated predominantly 
through topoisomerase II12, 28, 29 HDACIs sensitise cells to topoisomerase poisons including 
etoposide, but the sensitisation is reported to be dependent upon topoisomerase II12 This apparent 
contradiction can be resolved if HDACIs somehow recruit topoisomerase II as a target for 
topoisomerase poisons. A possible mechanism for this recruitment is provided by the chromatin 
decondensation, release of topoisomerase II from heterochromatic sites and a shift in the distribution 
of resulting topoisomerase II adducts towards the euchromatic portion of the nucleus that is induced 
by HDACIs. 
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Figure Legends 
Figure 1. Topoisomerase II staining co-localises with DAPI-bright and HP1 staining regions.  
(A) Mouse C127I cells were fixed with paraformaldehyde and permeabilised (see Materials and 
Methods) and processed for immunofluorescence with the anti-topoisomerase II rabbit antisera 
3535, 18513, 30400 or anti-topoisomerase II MAB H8,  and rat MAB MAC353  and were 
counterstained with DAPI. (B) C127I cells were similarly processed using anti-topoisomerase II 
rabbit antiserum 18511. Z-stacks of fluorescence images were captured. Deconvolved equatorial 
sections are shown. Scale in insert 4 m. 
Figure 2. Topoisomerase II is concentrated in chromocentres often surrounding nucleoli in 
mouse epithelial cells. (A) Cells were fixed and processed for immunofluorescence with anti-
topoisomerase II (green) and anti-fibrillarin or MAC353 (red) and were counterstained with DAPI. 
Z-stacks of fluorescence images were captured. Deconvolved equatorial sections are shown for the 
non-merged images. Equatorial xy planes together with xz and yz sections are shown for the merged 
images. Scale bar 10 m. (B) Cells were fixed and stained for topoisomerase IIor HP1 (green) and 
centromeres (CENP=B, red). 
Figure 3. TSA-mediated disassociation of topoisomerase II and HP1 from heterochromatin. 
C127I cells were cultured in media containing the indicated concentrations of TSA for two or five 
days before fixing and processing for immunofluorescence with the antibodies shown. Stacks of 
images were collected and deconvolved images were merged into maximum intensity projections. 
Figure 4. Quantification of topoisomerase II, HP1 and DNA content in C127I cells exposed 
for 5 days to 50 nM TSA. (A-C) Quantitative immunofluorescence images were collected at 10X. 
Horizontal bars = median values. (D) Western blot analysis of topoisomerase II and HP1. 5, 2.5 or 
1.25 g of protein from whole cells extracts were loaded as shown. Con – no treatment, TSA – 50 nM 
TSA 5 days. 
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Figure 5. Effect of TSA pre-treatment on the quantity of etoposide induced topoisomerase II-
DNA complexes. Cells grown on glass coverslips were either cultured in control medium or in 
medium containing 50 nM TSA for 5 days after which etoposide (50 M) was added to the medium. 
Two hours later cells were extracted in DRT buffer (see Materials and Methods). Quantitative 
immunofluorescence was carried out using the anti-topoisomerase II antibodies indicated. 
Figure 6. TSA alters the distribution of etoposide-induced topoisomerase II-DNA complexes in 
the nucleus. (A) Cells were cultured either in control medium or in medium containing 50 nM TSA 
for 5 days, after which etoposide (50 M) was added to the medium. Cells were extracted in situ 2 
hours later in DRT buffer before fixing (shown as “E”) or were immediately fixed with 
paraformaldehyde and permeabilised (shown as “F”, see Materials and Methods). 
Immunofluorescence was carried out using the anti-topoisomerase II antibody 18513. Image stacks 
were collected. Deconvolved equatorial sections are shown. Circled nuclei are enlarged and shown 
below. Bar=10 m. (B) Enlarged nucleus indicated by the circled nucleus in the first column of A, 
18513-stained. Bar=5 m. (C&D) Enlarged image of nucleus shown in the third column of A, stained 
with DAPI and 18513 (TopoII) respectively. (E&F) Enlarged image of nucleus shown in the fifth 
column of A, stained with DAPI and 18513 (TopoII) respectively. 
Figure 7. TSA alters the background pattern of histone H2AX phosphorylation. (A) TSA-treated 
or control cells were plated onto coverslips and subsequently exposed to medium containing 0 or 1 
M etoposide. Cells were fixed and processed for immunofluorescence using anti-H2AX and anti 
topoisomerase II (18513). Images were collected with a 40X objective, maximum intensity 
projections derived from deconvolved images are shown. In the first two columns, greyscale image 
levels were adjusted such that background (signal present in the absence of a DSB-inducing agent) 
H2AX was clearly visible. In the third column levels were adjusted as for the counting of induced 
H2AX foci, such that etoposide-induced H2AX foci are clearly visible but with minimal 
contribution from the background. (B) Quantitative immunofluorescent analysis of background 
H2AX intensity in control cells and cells treated with 50nM TSA for 5 days.  
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Figure 8. Topoisomerase II distribution and HDACI-induced redistribution in A549 lung 
cancer cells. (A) A549 cells were fixed with paraformaldehyde, permeabilised and immunostained 
with rabbit anti-topoisomerase II (green) and anti-fibrillarin MAB (red). In the lower row, cells were 
exposed to 2 mM VPA for 24 hours prior to fixation. (B) Control cells or cells treated with 2 mM 
VPA or 50 nM TSA for 48 hours were permeabilised prior to fixation as described in Materials and 
Methods (CSK extraction). Antibodies are as in (A). (C). Control, TSA treated or VPA treated cells 
were CSK extracted as in (B) and then fixed and immunostained with anti-rabbit topoisomerase II 
(18513) and mouse anti HP1.  In all cases equatorial confocal planes are shown. In the right-hand 
column of part (C) x-z and y-z confocal sections are also displayed for the topoisomerase II /HP1 
merged images. Scale bar = 10 m 
Figure S1. Topoisomerase II is concentrated in chromocentres surrounding centromeres in 
mouse epithelial cells and is redistributed following TSA treatment . Cells grown on glass 
coverslips were treated with TSA (50 nM 2 days) and fixed with methanol at -20ºC. Cells were 
inmmunostained for topoisomerase II (mouse monoclonal H8), CENP-B (rabbit polyclonal Abcam) 
and HP1 (rat monoclonal MAC353 Abcam). Z-stackes were recorded and deconvolution was carried 
out using Volocity software. Extended focus images projected from the deconvolved image stacks are 
shown.7 
Figure S2. Quantification of topoisomerase II-DNA adducts. Cells grown on glass coverslips 
were treated with TSA (5 days) or etoposide (2 hours) as indicated and either fixed by the standard 
procedure (Materials and methods, - Extracted) or were extracted with DRT buffer (Materials and 
methods, + Extracted) before fixation. Quantitative immunofluorescence was carried out using the 
anti-topoisomerase II antibodies indicated. 
Figure S3. Distribution of topoisomerase II in human lympoblasts. Cells plated on polylysine-
coated coverslips were either extracted with ice cold CSK buffer for 5 minutes and then fixed with 
paraformaldehyde (A &B) or were fixed and permeabilised without extraction as described in 
Materials and Methods (C). Fixed cells were processed for immunofluorescence with anti-rabbit 
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topoisomerase II (18513) and mouse anti-fibrillarin. Nalm6 and K562 are human leukaemia cells 
lines. Nalm6 
top2 Δ/ Δ
 is a top2 null derivative of Nalm6. 0.2 m z-sections, deconvolved equatorial 
sections are shown. Bar = 5 m. 
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TopoII poison Topoisomerase II 
Preference 
VPA pre-treatment 
(1.6mM) 
Potentiation 
Mitoxantrone 
 + YES
 
 - YES
1.6, 8 
mAMSA 
 + YES
 
 - YES
8
 
Etoposide  + YES
 
 - YES
8 
Doxorubicin  + NO 
 - NO 
Epirubicin N/D + NO 
 - NO 
 
Table 1.  Potentiation data obtained in A549 lung cancer cells for mitoxantrone, mAMSA, 
etoposide, doxorubicin and epirubicin, and the effect of the HDAC inhibitor VPA. Cells were 
either plated directly or pre-incubated with 1.6 mM VPA before plating into 96 well plates in media 
containing a range of topoisomerase poisons and either 0, 1.6 or 8 mM VPA.  Growth inhibition 
assays were performed and IC50 values were determined for each topoisomerase poison / VPA 
combination. Experiments were carried out at least in triplicate and potentiation values (PF50) were 
calculated (see Table S1). Where potentiation is scored as “YES”, IC50 values obtained with VPA 
were significantly lower than that obtained with topoisomerase poison alone (p<0.05 one tailed paired 
t-test). Topoisomerase II preference pertains to evidence for the relative involvement of 
topoisomerase II or – in mediating the cytotoxic effects in cell line systems (Errington et al., 1999; 
Toyoda et al., 2008) 
 
 
 
Mitoxantrone 
VPA pre-treatment /mM VPA co-treatment / mM IC50 /nM PF50 
0 0 96 ± 12  
0 1.6 40 ± 0* 2.4 ± 0.31 
0 8.0 23 ± 6.2* 4.6 ± 1.9 
1.6 0 43 ± 6.2* 2.3 ± 0.4 
1.6 1.6 23 ± 12* 5.8 ± 3.7 
8 0 43 ± 12* 2.3 ± 0.36 
8 8 100 ± 37 1.0 ± 0.28 
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mAMSA 
VPA pre-treatment /mM VPA co-treatment / mM IC50 /M PF50 
0 0 1.1 ± 0.50  
0 1.6 3.7 ± 0.20 3.0 ± 0.96 
0 8.0 0.16 ± 0.061* 6.1 ± 1.0 
1.6 0 0.30 ± 0.082* 3.4 ± 1.5 
1.6 1.6 0.17 ±0.047* 5.5 ± 1.5 
8 0 1.4 ± 0.43 0.66 ± 0.19 
8 8 0.77 ± 0.33 1.3 ± 0.58 
 
Etoposide 
VPA pre-treatment /mM VPA co-treatment / mM IC50 /M PF50 
0 0 7.7 ± 1.7  
0 1.6 4.7 ± 1.7 1.8 ± 0.62 
0 8.0 2.9 ± 0.94* 2.6 ±0.55 
1.6 0 4.7 ± 1.2 1.9 ± 1.0 
1.6 1.6 2.6 ± 0.65* 3.0 ± 0.08 
8 0 5.0 ± 0.82 1.5 ± 1.1 
8 8 4.2 ± 1.9 2.1 ± 0.47 
 
Doxorubicin 
VPA pre-treatment /mM VPA co-treatment / mM IC50 /nM PF50 
0 0 130 ± 47  
0 1.6 ND  
0 8.0 130 ± 120 2.3 ± 1.4 
1.6 0 150 ± 51 1.1 ± 0.67 
1.6 1.6 216 ± 62 0.71 ± 0.44 
8 0 193 ± 54 0.73 ± 0.24 
8 8 700 ± 250 0.20 ± 0.044 
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Epirubicin 
VPA pre-treatment /mM VPA co-treatment / mM IC50 /nM PF50 
0 0 190 ± 79  
0 1.6 ND   
0 8.0 153 ± 107 1.6 ± 0.59 
1.6 0 173 ± 38  1.3 ± 0.86 
1.6 1.6 140 ± 110 1.6 ± 1.0 
8 0 170 ± 180 1.1 ±0.31 
8 8 733 ± 368 0.44 ± 0.40 
 
Table S1.  IC50 values obtained in A549 lung cancer cells for mitoxantrone. mAMSA, etoposide, 
doxorubicin and epirubicin, and the effect of the HDAC inhibitor VPA. Cells were ether plated 
directly of incubated with VPA at the indicated concentration before plating into 96 well plates. 
Growth inhibition for the combinations of VPA and topoisomerase poisons indicated were 
determined.  * p<0.05 for significance of IC50 values being lower than that obtained with 
topoisomerase poison alone (one tailed paired t-test) 
Figures 
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